Inhaled aztreonam lysine: an evidence-based review

Bibliography

• O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373(9678):1891-904
   PubMed Web of Science ®Google Scholar
• Patient Registry Annual Data Report 2011. Bethedsa, MD: Cystic Fibrosis Foundation, 2012
   Google Scholar
• Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293(5):581-8
   PubMed Web of Science ®Google Scholar
• Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12(3):158-61
   PubMed Web of Science ®Google Scholar
• Emerson J, McNamara S, Buccat AM, et al. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010;45(4):363-70
   PubMed Web of Science ®Google Scholar
• Gruson D, Hilbert G, Vargas F, et al. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003;31(7):1908-14
   PubMed Web of Science ®Google Scholar
• Pujol M, Gudiol F. Evidence for antibiotic cycling in control of resistance. Curr Opin Infect Dis 2001;14(6):711-15
   Google Scholar
• CF Services Pharmacy Web Site. Available from: http://www.cfservicespharmacy.com/ProductsandPrices/CaystonAztreonamForInhalationSolutionAndThe [Cited 13 June, 2013]
   Google Scholar
• Assael B, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cystic Fibrosis 2013;2:130-40
   Google Scholar
• Product Informtion. Cayston (aztreonam for inhalation solution). Gilead Sciences, Inc; Foster City, CA: 2012
   Google Scholar
• Georgopapadakou NH, Smith SA, Sykes RB. Mode of action of aztreonam. Antimicrob Agents Chemother 1982;21(6):950-6
   Google Scholar
• Kirkby S, Novak K, McCoy K. Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review. Core Evid 2011;6:59-66
   PubMedGoogle Scholar
• Dietzsch HJ, Gottschalk B, Heyne K, et al. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics 1975;55(1):96-100
   PubMed Web of Science ®Google Scholar
• Sapienza MA, Kharitonov SA, Horvath I, et al. Effect of inhaled L-arginine on exhaled nitric oxide in normal and asthmatic subjects. Thorax 1998;53(3):172-5
   PubMed Web of Science ®Google Scholar
• Gibson RL, Retsch-Bogart GZ, Oermann C, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006;41(7):656-65
   PubMed Web of Science ®Google Scholar
• King P, Lomoskaya O, Griffith DC, et al. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother 2010;54(1):143-8
   PubMed Web of Science ®Google Scholar
• Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009;53(9):3847-54
   PubMed Web of Science ®Google Scholar
• Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011;9:32
   PubMed Web of Science ®Google Scholar
• McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178(9):921-8
   PubMed Web of Science ®Google Scholar
• Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45(11):1121-34
   PubMed Web of Science ®Google Scholar
• Retsch-Bogart GZ, Burns JL, Otto KL, et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008;43(1):47-58
   PubMed Web of Science ®Google Scholar
• Shawar RM, MacLeod DL, Garber RL, et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999;43(12):2877-80
   Google Scholar
• FDA Anti-Infective Drugs Advisory Committee. Aztreonam for Inhalation Solution (NDA 50-814) for Improvement of Respiratory Symptoms in Cystic Fibrosis Patients. 2009
   Google Scholar
• Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135(5):1223-32
   PubMed Web of Science ®Google Scholar
• Product Information. AZACTAM (aztreonam for injection). Bristol-Myers Squibb; Princeton, NJ: 2010
   Google Scholar
• Zeitler K, Salvas B, Stevens V, et al. Aztreonam lysine for inhalation: new formulation of an old antibiotic. Am J Health Syst Pharm 2012;69(2):107-15
   Google Scholar
• Kuhn RJ. Formulation of aerosolized therapeutics. Chest 2001;120(3 Suppl):94S-8S
   Google Scholar
• Prescribing information. Tobi (tobramycin for inhalation, USP). Novartis Pharmaceuticals Corp; East Hanover, NJ: 2009
   Google Scholar
• Wainwright CE, Quittner AL, Geller DE, et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. Journal of Cystic Fibrosis 2011;10(4):234-42
   PubMed Web of Science ®Google Scholar
• Tullis EBJ, Retsch-Bogart G, Bresnik M, et al. Aztreonam for inhalation solution (AZLI) in cystic fibrosis patients with chronic Burkholderia species (BURK) infection: inhitial results from a randomized, placebo-controlled trial (abstract 234). Pediatr Pulmonol 2011;46(Suppl 34):296
   Google Scholar
• Oermann CM, McCoy KS, Retsch-Bogart GZ, et al. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). J Antimicrob Chemother 2011;66(10):2398-404
   Google Scholar
• Cayston Access Program. Available from: https://http://www.cayston.com/cayston-access-program.html [Cited 13 June, 2013]
   Google Scholar
• Medi-Span. Available from: http://www.medispan.com/index.aspx [Cited 13 June, 2013]
   Google Scholar
• Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7):680-9
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Foundation Patient Registry: annual data report 2011. Available from: http://www.cff.org/livingwithcf/qualityimprovement/patientregistryreport [Cited 17 June, 2013]
   Google Scholar
• Pesaturo KA, Horton ER, Belliveau P. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes. Ann Pharmacother 2012;46(7-8):1076-85
   Google Scholar
• Hoiby N, Koch C. Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax 1990;45(11):881-4
   Google Scholar
• Doring G, Flume PA, Heijerman H, et al. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2011;11(6):461-79
   Google Scholar
• Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF (AZLI CAT). Available from: http://clinicaltrials.gov/show/NCT01641822 [Cited 15July, 2013]
   Google Scholar
• Aztreonam Lysine for Pseudomonas Infection Eradication Study (ALPINE). Available from: http://clinicaltrials.gov/show/NCT01375049
   Google Scholar
• Schechter MS, Trueman D, Farquharson R, et al. An economic evaluation of aztreonam lysine for inhalation and tobramycin for inhalation, in anintermittent aerosolised antibiotic regime, among cystic fibrosis patients with chronic pulmonary pseudomonas AerugINOSa infection. Am J Respir Crit Care Med 2012;185:A6733
   Google Scholar
• Cystic Fibrosis Foundation: drug development pipeline. Available from: http://www.cff.org/treatments/Pipeline Cited 14 June, 2013]
   Google Scholar